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1ABSTRACT
Background: The protective effect of Highly Active Antiretroviral Therapy (HAART) against Tuberculosis
(TB) may be affected by multiple factors. There is little or no information on the long-term impact of
HAART on the incidence of TB and associated risk factors in Ethiopia.
Objectives: To assess the incidence, risk factors and treatment outcome of TB in patients on HAART
Methods: This was long term cohort analysis with abstraction of data from medical records of patients
at Zewditu Memorial Hospital between September 11, 2006 and October 10, 2010. Patients classified as
free of TB at initiation of HAART were included in the analysis. They were routinely monitored and
screened for the occurrence of TB. Incidence of TB was estimated and bivariate and multivariate Cox
proportional regression model was fitted to determine the risk of tuberculosis.
Results: Total of 546 patients on HAART were enrolled in the analyses. The median duration of follow-up
was 23 months [inter quartile range (IQR); 5.8-38.2) and the median baseline CD4 count was 138 cells/µl
(IQR; 73-190). The incidence of TB for the cohort was 4.9/100 person-years (95% CI; 3.6-6.2). The
incidence significantly declined with duration on HAART reaching 0.2/100 person-years in the fourth
year (P<0.001 for trend). More than 60% of cases occurred in the first three months. Baseline CD4 cell
count <100 cells/µl [adjusted hazard ratio (AHR); 2.8 (95% CI; 1.6-4.9, P<0.001) and WHO clinical stage 3
or 4 (AHR; 2.2 (95%CI; 1.1-4.4, P=0.03) were independent risk factors for the occurrence of TB during
HAART. The highest incidence of TB was observed among patients with CD4 cell count <50 cells/µL (10.2
cases /100PY (95% CI; 4.8-15.5). Isoniazid preventive therapy (IPT) was not significantly associated with
an increased TB incidence in multivariate analysis but patients who received IPT have 10% higher TB-
free survival proportion compared with those with no IPT (P=0.03, log rank test). TB during HAART
carried bad prognosis with death rate of 29.1/100 person-years compared with 2.6/100 person-years
death rate for non-TB cases (P=0.02).
Conclusion: Incidence of TB is highest in the first 3 months and continues to decline in the first four
years. Advanced pre-treatment immunodeficiency is an important predictor of occurrence of TB during
HAART. Isoniazid preventive therapy may further reduce incidence of TB in patients receiving HAART.
Recommendation: Comprehensive TB control measures including stringent screening of TB before
initiation of HAART should be implemented consistently to reduce burden of TB among HIV infected
individuals. HAART should be initiated at higher CD4 cell count as recommended in the national
guideline to reduce incidence of TB. Other adjunct strategies like IPT if implemented consistently can
help to further reduce risk of TB in HIV patients.
21. INTRODUCTION
The interaction between Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) infection
is complex. HIV infection weakens the immune system and increases susceptibility of
individuals to TB.  HIV infection is also an established risk factor for reactivation, re-infection
and progression of latent TB infection to active diseases. Moreover, it alters the clinical
presentation of TB, complicates the follow-up and compromises the response to anti-TB
treatment (1). HIV-positive people are 20 times at higher risk to develop TB compared to HIV-
negative people in countries with a generalized HIV epidemic (2). Therefore, TB is the most
common opportunistic infection among HIV-infected patients, who remain at higher risk for TB
throughout the course of their disease specially in African setting.
The recent increase in worldwide prevalence of HIV infection has contributed to the rising global
incidence of tuberculosis. Of the estimated 9.4 million new TB cases that occurred worldwide in
2009 for example, 1.2 million (13%) were associated with HIV and the African region accounted
for 80% of the global burden of HIV-associated TB. In Ethiopia, infection with TB is a major
public health problem with an estimated annual incidence of 168 cases per 100,000 population
for smear positive tuberculosis and 378 cases per 100,000 populations for all forms of TB (2).
Similarly, the rate of TB/HIV co-infection is high and depends on the prevalence of HIV
infection in community. Studies have shown that the TB/HIV co-infection rate in Ethiopia was
variable ranging from 18-52% (3-6). In addition, one population-based study demonstrated
strong positive association between the prevalence of HIV infection and incidence of all forms of
TB (7).
3The current TB control strategy of case-finding and directly observed treatment of sputum
smear-positive patients using short-course anti-tuberculosis treatment (DOTS) has not been
effective to contain HIV-related TB epidemic (8). The World Health Organization (WHO)
formulated a strategic framework where highly active antiretroviral treatment (HAART) is an
important element (8). Studies have shown that TB incidence is reduced by two-thirds in HIV
infected cohorts receiving HAART in both high-income and resource-limited settings (9, 10).
The effect of HAART in reducing TB incidence has been shown to be time-dependant with most
benefits occurring during the first 2-3 years of treatment. The risk reduction is directly related to
increases in blood CD4 cell counts and to the restoration of TB-specific immune responses.  CD4
cell count increase from <100 cells/µl to >500 cells/ µl was associated with a 10-fold reduction
of risk of TB (11). In Ethiopia almost 90% reduction in TB incidence was observed during one
year follow-up period in HIV positive cohorts who received HAART compared to Pre-
antiretroviral therapy (ART) patients followed in the same facility (12).
Increasing evidences suggest that, unlike low virulent pathogens, significant rates of TB persist
during HAART (13, 14). Even though the incidence of TB is greatly diminished during
treatment, the risk remains substantially higher. This has important implications for the extent to
which HAART may assist in TB control in low income countries (14). Studies have identified
factors that are associated with high incidence of TB during HAART. Low baseline CD4 count
(<100cells/μl), WHO clinical stage of the disease (Stage 3 or 4), younger age and previous
history of TB were important risk factors for high incidence of TB among patients receiving
HAART (15, 16). The use of Isoniazid preventive therapy (IPT) was associated with lower risks
of TB (16). Another study has described past history of TB as the only factor for an increased
4risk of TB during HAART (17). Most studies used data from cohorts with short median duration
of follow-up. Long term effect of HAART on TB incidence needs to be studied further.
In Ethiopia, much has not been done to know long term effect of HAART on the incidence of
TB. One study in a district hospital in Southern region showed 3.7 per 100 person years (PY) of
observation TB incidence in patients receiving HAART (12). This was based on the emergence
of 6 new TB cases only after 50 weeks of follow-up of 180 patients receiving HAART. Risk
factors for an increased incidence of TB during HAART have not been well characterized.
Understanding the different factors related to the occurrence of TB during ART is critical for
better care of patients and will also be helpful to guide the programs. This study was therefore,
aimed at determination of the incidence of TB and associated risk factors in patients receiving
HAART at Zewditu Memorial Hospital from September 11, 2006 to October 10, 2010.
52. LITERATURE REVIEW
2.1. Human Immunodeficiency Virus (HIV) infection and global burden of
Tuberculosis
Infection with Mycobacterium tuberculosis (MTB) remains one of the leading causes of
morbidity and mortality globally (18). The growing burden of multidrug-resistant (MDR) and
extensively drug-resistant (XDR) cases of TB poses additional challenges to TB case
management. Of the estimated 9.4 million new cases of TB that occurred in 2009, 1.2 million
(13%) were co-infected with HIV. African region accounted for approximately 80% of the
burden of TB-HIV co-infections, followed by South-East Asia (11%). In 2009, there were
380,000 TB-related deaths among HIV-positive patients accounting for 23% of the global
HIV/AIDS mortality. Globally, an estimated 33 million people are infected with HIV (2).
HIV-positive people are about 20 times more likely than HIV-negative people to develop TB in
countries with a generalized HIV epidemic (2). Ethiopia is home for an estimated 1.1 million
people living with HIV with adult HIV prevalence estimated to be between 1.4-2.8% (19).
Infection with TB is also a major public health problem in Ethiopia with an estimated annual
incidence of 168 cases per 100,000 population for smear positive tuberculosis and 378 cases per
100,000 populations for all forms of TB (2). HIV related tuberculosis is an important challenge
for the TB control program. The TB/HIV co-infection rate is variable (18-57%) depending on the
prevalence of HIV in the community (3-6).
62.2. HIV infection and DOTs program
The current TB control strategy-Directly Observed Treatment Short course (DOTS) was not
effective in curving the TB epidemic specially in countries with high burden of both diseases.
This relates to the fundamental epidemiological interaction between TB and HIV both of which
are important public health problems in African settings. The principle underlying DOTS is to
diagnose and effectively treat infectious pulmonary TB cases and thereby reduce onward
transmission and avert secondary cases. However, DOTS does not prevent reactivation of latent
TB infection (LTBI) which commonly is the case with HIV co-infection. In those with HIV co-
infection, subsequent risk of developing TB through reactivation of LTBI is extremely high, with
overall rates reaching as high as 20-30% per year specially in those with the most advanced
immunodeficiency (20, 21). In addition, DOTS does not reduce the very high susceptibility of
HIV-infected individuals to develop rapidly progressive disease following exposure.
The reduction in the transmission risk in the community achieved through expansion of DOTS
program was out-weighed by many-folds by the greatly increased risk of rapidly progressive
disease in HIV-infected people who are nevertheless exposed. Major increases in incidence rates
of TB may further contribute to transmission, although this is off-set to some extent by the fact
that HIV-associated TB cases are generally less infectious than disease in HIV-uninfected people
(21). Without addressing the impact of HIV on TB epidemic, DOTS and other interventions will
not be successful in curving the tide of TB epidemic. High incidence rates of HIV-associated TB
and associated high mortality risk are driven by immunodeficiency as reflected by the blood CD4
cell count. Without addressing this, approaches to TB control are flawed and hence World Health
Organization (WHO) launched a Stop TB strategy in 2006 which emphasizes the TB/HIV co-
7infection (22). Therefore, HAART must clearly be central to both TB treatment and prevention
strategies.
2.3. Effect of HAART on TB incidence
Studies have shown that TB incidence is reduced by two-thirds in HIV infected cohorts receiving
HAART in both high-income and resource-limited settings (9, 10). One prospective cohort study
in Ethiopia indicated that the incidence of TB was 3.7/100 person-years (PY) in patients
receiving HAART and 11.1/100 PY in Pre-ART patients indicating a 3 times lower risk of TB
among those taking HAART (12).  This was however; based on 185 pre-ART and 180 ART
patients followed for less than a year and the long term effect of HAART on TB was not well
described. The effect of HAART in reducing TB incidence has been shown to be time-dependant
with most benefits occurring during the first 2-3 years of treatment (10). The risk reduction is
directly related to increases in blood CD4 cell counts and to the restoration of TB-specific
immune responses.  CD4 cell count increase from <100 cells/µl to >500 cells/ µl was associated
with a 10-fold reduction of risk of TB (11). The TB preventive effects of HAART are observed
across a wide spectrum of baseline CD4 cell counts, including those with the very lowest counts
and benefits work well in those with and without evidence of latent tuberculosis infections.
HAART also reduces TB risk in those with a history of previous TB, with an approximate
halving of TB recurrence rates. Thus, HAART is potentially a potent preventive tool for
addressing the HIV-associated TB epidemic. In addition, HAART transforms the prognosis of
patients with HIV-associated TB, reducing mortality risk by 64-95% (10). It is therefore,
absolutely essential that all patients with TB are HIV-tested so that those who test positive may
receive the benefits of HAART, Isoniazid prophylactic therapy (IPT) and co-trimoxazole
8preventive therapy (CPT). The national guideline in Ethiopia recommends HIV testing for every
TB patients and TB screening for every HIV patients.
2.4. Occurrence of TB during HAART
Even though the TB risk reduction observed in individuals receiving HAART is very substantial,
the long term effect of HAART in reducing the risk of TB may be limited due to multiple
factors.  Limited proportion of HIV-infected population has been reached and achieving high
coverage will be resource- intensive and challenging. For example, in Ethiopia less than 50% of
HIV positive patients that required treatment are currently receiving therapy. Patients entering
ART program typically have low CD4 cell counts and many of them could present with TB as a
first symptom. More than 30% of HIV positive patients in Ethiopia come with a CD4 cell count
less than 100 cells/µl (23). Among HIV-infected individuals who are not receiving HAART, risk
of TB increases with increasing HIV-associated immunodeficiency (24). Patients with most
advanced pretreatment immunodeficiency as indicated by both blood CD4 cell count and WHO
clinical stage retain the highest risk of TB during HAART. This may reflect the fact that the
greater the degree of pre-HAART immunodeficiency, the more prolonged the period of
treatment required to restore immune function. Moreover, advanced pretreatment
immunodeficiency also limits the extent to which immune functions can be restored in the long
term (25, 26). The incidence of TB for example, was 3.6 times higher among patients whose
CD4 count during the initiation of ART was <100 cells/µl compared to those whose CD4 cell
count was >100 cells/µl (15). Treatment guideline in Ethiopia considers advanced disease (WHO
stage 3 or 4) and CD4 cell counts < 200 cells/μl for initiation of HAART (27). Treatment
according to these recommendations may limit the extent to which long-term TB-specific
9immune responses may be restored in many patients and this may restrict the potential benefits
of widespread use of HAART in a TB control program to reduce the incidence of tuberculosis.
During long-term HAART, TB incidence rates remain several-fold higher than rates among
HIV-uninfected people living in the same community (9, 10) and this risk is likely to be
sustained throughout their life-span. Their life-span in turn is greatly increased by HAART and
so cumulative risk of TB over time will remain high. TB risk may remain high in some patients
due to poor immunological response to HAART, poor treatment adherence, ART failure,
nosocomial TB transmission (resulting from treatment in hospital) or being lost to follow-up. As
a result of the above factors, the cumulative lifetime risk of TB in patients enrolled in ART
programs may therefore remain extremely high (9-11). Tuberculosis recurrence after previous
diagnosis and treatment results either from endogenous relapse or disease after re-infection with a
different mycobacterium strains (28). Recurrence is significantly increased in HIV-infected
persons. Therefore, prior history of tuberculosis is an important risk factor for subsequent
occurrence of TB in patients receiving HAART. The incidence in patients with a prior history of
tuberculosis can be as high as 11.3/100 person-years compared with 3.0/100 person-years in
those without prior tuberculosis with adjusted hazard ratio of 4.6 (17). Both re-infection and
relapse play a part, with re-infection being more likely in HIV-infected than uninfected persons,
especially in high transmission areas, as well as in persons in whom recurrence is more distant in
time from initial treatment (29, 30).
The use of IPT reduces the risk of TB but combination of IPT and HAART lowers the risk
significantly suggesting that the provision of antiretroviral drugs (ARVs) and tuberculosis
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preventive therapy could have a more substantial impact on HIV-related tuberculosis than either
strategy alone (16). In terms of timing, the incidence of TB was very high in the first three
months after HAART initiation, especially in patients with very low CD4 counts, and likely
contributes to high early mortality (31).
2.5. Socio-demographic Factors and Incidence of TB among patients receiving HAART
Younger age was identified as risk factor for TB during HAART. The mechanism was unclear
but was suggested possibly to reflect behavioral differences that affect exposure to HIV infection
(15, 16). Male gender was also associated with the higher risk of TB in a multivariate analysis
even though sound scientific explanation was not given (31). Other socio-demographic factors
were not significantly associated with an increased risk of TB during HAART.
2.6. Rationale of the study
In Ethiopia, there has not been much work to describe the long term effect of HAART on the
incidence of TB. Risk factors for TB among HIV positive patients receiving HAART were not
well characterized. Such information helps in the management of patients and provides guidance
to the programs. In addition, it will also serve as baseline information for further impact analysis
of effectiveness of HAART for the reduction of the TB burden. Therefore, this study was aimed
at determination of the incidence and risk factors of TB in patients receiving HAART at Zewditu
Memorial hospital from September 11, 2006 to October 10, 2010. The hospital is model ART
and VCT center with more than 6000 patients currently on HAART.
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3. OBJECTIVES
3.1. General Objective
 To assess the incidence, risk factors and treatment outcome for TB in patients receiving
HAART
3.2. Specific Objectives
 To determine the incidence of TB in patients receiving HAART
 To describe risk factors of TB among patients receiving HAART
 To explore treatment outcome of incident TB cases receiving HAART
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4. METHODS
4.1 Study area/Context
ART clinic at Zewditu Memorial Hospital was established in July 2003. The free ART program
in this clinic was initiated in March 2005. This is the first and the largest clinic in the country and
serving about 15,335 clients. Each day, on average, 20 new clients and 200 repeat cases are
served.  It is now an important ART training and research center and continues to be model ART
and Voluntary Counseling and Testing (VCT) center in Ethiopia. The main activities of the ART
clinic are enrolling HIV positive patients in to chronic care and follow-up, assessment of patients
for ART eligibility, adherence counseling and initiation of ART, and prophylaxis and treatment
of opportunistic infections. The TB/HIV collaborative activities like intensive case finding, INH
prophylaxis, infection prevention and referral of TB patients to DOTs clinic are core components
of routine patient care.
Between July 2003-2010, 5,977 adult and 506 pediatric patients have been taking HAART and
21 patients were on second line treatment. However, the number of patients ever started on
HAART was very large, 9881. There were 1, 372 dropouts, 1,687 transferred outs and 826
deaths in the same period as factors for the gap between ever started and currently on HAA RT.
Twelve percent of HIV positive patients had TB and 25.4% of TB patients were positive for
HIV. The clinic has two medical doctors providing ART services, 5 regular nurses, 3 advanced
ART nurses, 5 data clerks, 1 pharmacist, 2 druggists, 3 lab technicians, 1 pediatrics ART
Physician, 2 pediatrics ART nurses and 7 adherence supporters (people living with HIV). The
hospital uses standardized monitoring and evaluation tools and the data collection and
management process is well controlled and supported by electronic data back-up and processing.
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4.2. Source and Study Population
The study was conducted at Zewditu Memorial Hospital where there were 5,997 patients
receiving HAART. The actual study population was patients newly enrolled in ART program
from September 11, 2006 to October 10, 2010. This period was selected since the facility started
full implementation of standardized formats, documentation and recording system in regular
manner during this period. This was critical since the study was based on secondary data and it
was important to make sure that important variables for the study should be available for all
enrolled subjects in the study. The likelihood of obtaining complete information on the variables
for the study was very high during this period.
4.2.1. Inclusion criteria
 All HIV positive patients with age greater than or equal to 15 years who started HAART
between September 11, 2006 to October 10, 2010.
 HIV positive patients on HAART, who have baseline CD4 determination and at least one
additional prospective follow-up at the facility
4.2.2. Exclusion criteria
 HIV positive patients on HAART with incomplete clinical records (intake forms, Pre-
ART and ART registers and follow-up forms)
 All transferred in HIV patients on HAART. Baseline clinical and socio-demographic
information for these patients exists only in facilities where they started HAART
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 HIV positive patients who have been taking treatment for tuberculosis at the time of
initiation of HAART (however, all patients who have completed tuberculosis treatment
before initiation of HAART or have TB treatment history were included)
The risk of TB among patients receiving HAART was assessed using the person-time method.
Follow-up was censored at date of TB diagnosis, or death or the date of the most recent visit.
Patients who died during the follow-up were censored on the date of their last clinic visit, as it
was difficult to verify the exact dates of death.  All the exposures and outcomes were abstracted
from patient medical records. The main outcome of interest was the occurrence of TB among
patients taking HAART at any point in the follow up period. Tuberculosis was diagnosed in
patients presenting with the signs and symptoms suggestive of tuberculosis on the basis of chest
radiographs, sputum and other body fluid smear microscopy (AFB), fine needle aspiration (FNA)
and response to anti-tuberculosis therapy.
4.3. Study Design
This was a retrospective cohort study on adult patients taking HAART and being followed at
Zewditu Memorial Hospital from September 11, 2006 to October 10, 2010. Information was
retrieved on the socio-demographic factors, WHO stage of HIV at enrollment, CD4 counts at
enrollment and on intervals then after (6 month, 12 month, 18 month, 24 month, 30 month and
36 months of follow-up), viral load information if available, previous history of TB, occurrence
of TB during follows up and length of follow-up before developing TB. In addition, the type of
tuberculosis (smear positive pulmonary, smear negative pulmonary or extra-pulmonary) was
noted. Data on IPT and outcome of treatment of patients with TB during the follow up period
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were collected. The data on different dependent and independent variables were collected from
ART register, HIV care/follow up charts, TB treatment register and medical records.
4.4. Sample Size and Sampling Procedure
Studies have indicated that 3-10% of patients receiving HAART develop any form of
tuberculosis in subsequent years (12, 15, 31). For the first objective of the study, by taking 10%
as proportion of patients developing new TB while receiving HAART, with a precision of 3%
and confidence interval of 95%, the sample size was:
n=Zα/22p(1-p)/d2
n=1.962(.1x.9)/.032
n=384
To assess the risk factors for tuberculosis in patients receiving HAART, the difference between
two sample proportions sample size calculation formula was employed. Studies have indicated
that baseline CD4 count is an important factor associated with the subsequent occurrence of TB
in patients receiving HAART. One long term follow-up study in South Africa for example, has
indicated that the incidence of TB in patients enrolled in to ART program at baseline CD4 count
of less than 100 cells/µl was 5.7/100 person-years (12 new TB cases among 73 patients
followed) as compared to 1.6/100 person-years (15 new TB cases from 273 patients followed)
for those enrolled at baseline CD4 count of >100 cells/µl [Adjusted risk ratio 2.38, p=0.04] (15).
In Ethiopia, facility reports have indicated that one-third of patients start HAART at CD4 count
<100 cells/µl. At 95% confidence interval and 80% power of test and 1:2 ratio between exposed
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(CD4 count <100) and unexposed (CD4 count >100 cells/µl), the sample size for each categories
was:
n1= Zα/2√[1+1/r]P(1-P)+Zβ√p1(1-p1)+p2(1-p2)/r
(p1+p2)2
n1=the required sample size for the exposed (CD4 <100)
n2=the required sample size for the non-exposed (CD4 >100)
n1:n2=1:2
p1=proportion of TB in exposed
p2=proportion of TB in non-exposed
P=p1+rp2/1+r
r=n2/n1
α=type-I error (0.05)
Zα/2=Critical value at 95% level of confidence
Zβ=standard normal distribution value corresponding to the power
n1= 184 and n2=362 making the total sample size 546. Similar calculations were made for
other variables but the sample size calculated for CD4 count was maximum number and was
taken to be the final sample size for the study.
In cohort study, the point of entry of patients to the study and the duration of follow-up are
important parameters. Therefore, 546 subjects (184 with CD4 count <100cells/µl and 362 with
baseline CD4 count >100cells/µl) were distributed to each month of the study period from
September 2006 to October 2010 proportional to the number of subjects in each categories
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enrolled in each month. Once this was determined, the actual study subjects from each month
were selected by simple random sampling. Identification number of subjects enrolled to HAART
in each month for both categories was retrieved from the electronic data base and the study
subjects were selected by the lottery method until the sample size allocated for that month was
reached and similar procedures were applied to the entire study period. The occurrence of new
tuberculosis (either re-infection or reactivation) is the dependent variable and all socio-
demographic and clinical characteristics of patients are independent variables.
4.5. Data Collection Procedure
Information on socio-demographic variables, baseline and subsequent CD4 test results, whether
patients were on first or second line ART, the previous TB treatment status, occurrence of TB
during follow-up, treatment outcome and other related variables were collected from the patient
records (ART register, HIV care/follow up charts, TB treatment register and medical records)
using well designed and pre-tested questionnaire. The available information on the patient
records were first observed and appropriate data collection tool was developed with an input by
experts working at the site.
Zewditu memorial hospital is one of the hospitals where health management information system
(HMIS) is implemented. HMIS is a very important initiative by Federal Ministry of Health
(FMOH) and hence there is stringent data quality control system in place. The data management
system gets a lot of support from partners. President’s Emergency Plan for AIDS relief
(PEPFAR)-Ethiopia and John Hopkins University (JHU), partner of United States Centers for
Disease Control and Prevention in Ethiopia (CDC-Ethiopia), has been providing technical
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support throughout data collection process. The data base is in the electronic system and this
facilitated retrieval of patient registration number. Patient charts were retrieved using the patient
registration number which was a unique identifier. All data were retrieved from the patient
follow-up charts. For missing elements like treatment outcome and INH provision especially for
incident TB cases, pre-ART and TB registers were additionally used. Quality of data has been
checked and there were dedicated data clerks working in ART section. The JHU monitoring and
evaluation team and clinical team at Zewditu Memorial Hospital regularly monitor the quality of
the data.
One trained nurse working at TB clinic and one data manager in the ART section were employed
for the data collection. Even though both know all the processes and procedures of data
management in the facility, they were trained on how to retrieve data for this study and were
provided with written standard operating procedures. They were briefed on the definition of
variables on the questionnaire and how to retrieve the variables from their data base system. The
sample retrieval process was closely monitored by the principal investigator throughout the data
collection period. Completed questionnaires were checked regularly for completeness of
information and any gaps identified were immediately communicated to the data collection team.
4.6. Data Analysis
Data was entered to Epi Info version 3.3.2 and was cleaned before analysis. SPSS software
(PASW statistics 18, 1993-2007) was used for the analysis. Subjects in each CD4 count category
were characterized by their socio-demographic and clinical characteristics. The difference in
proportions was compared by X2 test. The incidence density rate (IDR) was calculated for the
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entire study period for the two categories of study subjects. IDR was also calculated for each
year of the study to see if there was any difference in the IDR through time. IDR was defined as
the number of new episodes of TB occurring per 100 patient-years of observation. This analysis
was further stratified by WHO clinical staging (stage 3 or 4 versus stage 1or 2), socioeconomic
status, previous history of TB, age, base-line hemoglobin (<10 gm/dl or >10 gm/dl) and gender.
Subjects were categorized by the CD4 count at the design stage. The CD4 count <100 was used
as cutoff as this has been indicated as significantly and independently associated with risk of TB
in another cohort study elsewhere (15). However, incidence was also calculated for low CD4 cell
count (<50 cells/µl). Kaplan-Meier plots were used for analysis of probabilities of not
developing TB. TB-free survival was defined as the time from enrolment to HAART to the date
of TB diagnosis, death from any cause or the last follow-up visit. TB-free survival again was
stratified further by baseline immunological and clinical status and was compared using the
generalized log rank test. Bivariate and multivariate Cox proportional hazards regression models
were fitted to determine the risk of TB, which was expressed as a rate ratio. Variables were
considered for inclusion into the multivariate model if their p-value in bivariate analysis was
<0.3. All tests were two sided and a P value of 0.05 was considered significant.
4.7. Operational Definitions
 New or incident TB in this study was defined as the occurrence of TB (new infection or
reactivation of latent TB) in HIV patients any time after HAART. The type of TB can be
smear positive pulmonary, smear negative pulmonary, extra-pulmonary or disseminated
tuberculosis as identified by signs and symptoms, laboratory and/or X-ray diagnosis.
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 Duration of follow-up was the time from initiation of ART until occurrence of TB for the
incident TB cases and until the last follow-up period for non-TB subjects, transferred
outs, dead or lost to follow-up.
4.8. Ethical Consideration
This study was based on the secondary data collected after routine clinical care for HIV patients.
Patients get the service according to the national guidelines and data were recorded after each
service. Patients have been followed based on program requirements. There was no any intention
to collect any additional information from patients and there was no collection of any patient
samples for this purpose. In addition, the study protocol was cleared by the Institutional Review
Board (IRB) of University of Gondar. Support letter was obtained from Addis Ababa Regional
Health Bureau. Permission was sought from the management of the Zewditu Memorial hospital
to use the secondary data for the purpose of this study. The results were kept confidential and
there were no any personal identifiers attached during data retrieval in this study. The
information generated from this study will be helpful for better management of patients with
TB/HIV co-infection and will be an input for guiding the program. It can also serve as baseline
information for long term impact analysis of HAART on prevention and control of tuberculosis.
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5. RESULTS
5.1. Cohort Characteristics
Between September 11, 2006 and October 10, 2010, cohorts of 546 patients receiving HAART at
Zewditu Memorial Hospital, Addis Ababa were retrospectively selected. Data were collected
through a retrospective medical record review. At base line, the median age of the cohort was 36
years (range, 17-70) with most study subjects under the age group of 30-44 years. Females
accounted for 58.8% of patients enrolled and 84.5% of study subjects had secondary education or
lower. Majority (71.4%) of subjects was either married or single and 80.4% were orthodox
Christians. Significant number (44.9%) was unemployed. The median base-line CD4 cell count
was138 cells/µl (IQR; 73-190, range; 5-638). Total of 184 (33.7%) of patients had baseline CD4
count of <100 cells/ µl and 362 (66.3%) had baseline CD4 cell count of >100 cells/ µl. Forty-
eight (8.8%) of subjects had baseline hemoglobin (Hgb) of <10gm/dl, 355 (65%) of patients had
symptomatic disease (WHO clinical stages 3 or 4); and 94 (17.2%) had a previous episode of
tuberculosis (Table 1).
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Table 1: Baseline characteristics of patients on HAART at Zewditu Memorial Hospital
September 11, 2006 to October 10, 2010
TB=tuberculosis, NA=not available, WHO=World Health Organization
Characteristics CD4 <100 cells/µl
Frequency (%)
n=184
CD4 > 100 cells/µl
Frequency (%)
n=362
Total
Frequency (%)
N=546
Age
15-29 41 (22.3) 65 (17.9) 106 (19.4)
30-44 115 (62.5) 233 (64.4) 348 (63.7)
>45 28 (15.2) 64 (17.7) 92 (16.8)
Sex
Male 84 (45.7) 141 (39.0) 225 (41.2)
Female 100 (54.3) 221 (61.0) 321 (58.8)
Marital Status
Never married 60 (32.6) 83 (22.9) 143 (26.2)
Married 69 (37.5) 178 (49.2) 247 (45.2)
Separated/divorced 26 (14.1) 45 (12.4) 71  (13.0)
Widowed 29 (15.8) 56 (15.5) 85  (15.6)
Religion
Orthodox 142 (77.2) 297 (82.0) 439 (80.4)
Muslim 19 (10.3) 24 (6.7) 43 (7.9)
Protestant 22 (12.0) 38 (10.5) 60 (11.0)
Catholic 1 (0.5) - 1 (0.2)
Others - 3 (0.8) 3 (0.5)
Educational status
No education 26 (14.1) 36 (9.9) 62 (11.4)
Primary 53 (28.8) 124 (34.2) 177 (32.4)
Secondary 79 (42.9) 143 (39.5) 222 (40.7)
Tertiary 25 (13.7) 53 (14.7) 78 (14.3)
NA 1 (0.5) 6 (1.7) 7 (1.3)
Occupation
Employed 64 (34.8) 125 (34.5) 189 (34.6)
Unemployed 85 (46.2) 160 (44.2) 245 (44.9)
NA 35 (19.0) 77 (21.3) 112 (20.5)
WHO stage
Stage 1 or 2 44 (23.9) 147 (40.6) 191 (35)
Stage 3 or 4 140 (76.1) 215 (59.4) 355 (65)
Baseline hemoglobin
<10gm/dl 23 (12.5) 25 (6.9) 48 (8.8)
>10gm/dl 161 (87.5) 334 (92.3) 495 (90.7)
NA - 3 (0.8) 3 (0.5)
Previous TB history
Yes 43 (23.4) 51 (14.1) 94 (17.2)
NO 140 (76.1) 305 (84.2) 445 (81.5)
NA 1 (0.5) 6 (1.7) 7 (1.3)
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The median duration of follow-up was 23 months (IQR; 5.8-38.2, range; 0.3-52.6).  At the end of
follow-up, 487 (89.2%) of patients were still on treatment, 26 (4.8%) were lost to follow-up or
transferred out and 33 (6%) had died.   The predominant highly active antiretroviral (HAART)
regimens initially prescribed were combination of Zidovudine, Lamivudine and nevirapine
(30.4%), zidovudine, lamivudine and efivarenz (24.7%) followed by stavudine,  lamivudine and
nevirapine (17.6%). Only 3 (0.5%) patients were switched to second line anti-retroviral therapy
due to treatment failure  and 144 (26.4%) of subjects developed side effects to medication that
required regiment substitution. Cotrimoxazole preventive therapy (CPT) was provided to 511
(93.6%) of patients and 65 (11.9%) received IPT (Table 2).
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Table 2: Characteristics after follow-up of patients on HAART at Zewditu Memorial
Hospital September 11, 2006 to October 10, 2010
Characteristics CD4 <100
cells/µl
Frequency (%)
n=184
CD4 > 100
cells/µl
Frequency (%)
n=362
Total
Frequency (%)
N=546
Cohort Status (last follow-up date)
Still on HAART 148 (80.4) 339 (93.7) 487 (89.2)
Lost to follow-up or transferred out 11 (6.0) 15 (4.1) 26 (4.8)
Dead 25 (13.6) 8 (2.2) 33 (6.0)
Initial regimen
D4T/3TC/NVP 40 (21.7) 56 (15.5) 96 (17.6)
ZDV/3TC/NVP 49 (26.6) 117 (32.3) 166 (30.4)
D4T/3TC/EFV 35 (19.0) 29 (8.0) 64 (11.7)
ZDV/3TC/EFV 43 (23.5) 92 (25.4) 135 (24.70
Others 17 (9.2) 68 (18.8) 85 (15.6)
Regimen switched to Second line
Yes - 3 (0.8) 3 (0.5)
No 184 (100) 359 (99.2) 543 (99.5)
Developed side effect for HAART
Yes 45 (24.5) 83 (22.9) 128 (23.4)
No 139 (75.5) 279 (77.1) 418 (76.6)
IPT provided
Yes 3 (1.6) 62 (17.1) 65 (11.9)
No 181 (98.4) 300 (82.9) 481 (88.1)
CPT provided
Yes 172 (93.5) 339 (93.7) 511 (93.6)
No 12 (6.5) 23 (6.3) 35 (6.4)
IPT= Isoniazid preventive therapy; CPT=cotrimoxazole preventive therapy
5.2. New Tuberculosis Cases
There were 51 new TB cases out of the 546 patients included in the analysis (9.3%). Among the
cases, 27 (53%) were extra-pulmonary and/or disseminated, 22 (43%) were smear negative
pulmonary and 2 (4%) were smear positive pulmonary TB cases. The median age for the TB
cases was 35 years with range of 24-53 and females accounted for 54.9% of new TB cases. Six
(11.8%) of cases had past TB history, only one case had received IPT while 96.1% of new TB
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cases had received CPT. Eighteen cases (35.3%) developed side effects for anti-retroviral
treatment that warranted regimen substitution (Table 3). The median duration of follow-up for
the TB cases was 1.8 months (IQR; 0.7-7.0, range; 0.3-43.7)). The median base-line CD4 cell
count was 86 cells/ µl (IQR 45-139, range; 7-247).  Twenty-four cases (47.1%) were on NVP
containing regimen, which in 39% of cases required substitution by EFV due to fear of liver
toxicity. The cases are presumptive cases based on sputum smear microscopy, chest x- ray,
pathological evidence, clinical signs and symptoms and response to therapy. TB culture was not
being done routinely.  All 51 episodes of TB occurred with the first four years of follow-up and
majority (60.8%) occurred in the first 3 months after initiation of HAART and 82.4% of cases
had already occurred in the first year of follow-up. Only 3.9% of cases occurred after 2 years on
HAART (Fig 1.).
5.3. Tuberculosis treatment outcome for incident cases
Forty of the new tuberculosis cases (78.4%) had completed treatment or were cured, 7 (13.7%)
had died and more deaths for TB cases occurred among patients with CD4 count of less than 100
cells/µ1 (85.7%), 2 (3.9%) were still on treatment during the last follow-up but treatment
outcome could not be verified for 2 (3.9%) patients (Table 3). Of 33 deaths in the entire cohort, 7
(21.2%) were among those diagnosed with TB during the follow-up even though verification of
causes of death was not possible from records. The mortality rate was compared between
patients receiving HAART who remained free of TB until the last date of follow-up and those
who developed TB in the course of treatment. There were 7 deaths among new TB cases after
24.04 person-years of follow-up giving death rate of 29.1/100 person-years (95% CI; 7.5-50.7).
On the other hand, there were 26 deaths among patients on HAART who remained free of TB
until the last follow-up period after 1015.32 person-years of follow-up; death rate of 2.6 per 100
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person-years (95% CI; 1.6-3.5). The difference observed was statistically significant (P=0.02)
indicating that TB occurrence during HAART carried poor prognosis.
Table 3: Characteristics of incident tuberculosis cases at Zewditu Memorial Hospital
September 11, 2006 to October 10, 2010
Characteristics CD4 <100
cells/µl
Frequency (%)
CD4 > 100
cells/µl
Frequency (%)
Total
Frequency (%)
Patient developed TB
Yes 30 (16.3) 21 (5.8) 51 (9.3)
No 154 (83.7) 341 (94.2) 495 (90.7)
Sex
Male 15 (45.5) 8 (44.4) 23(45.1)
Female 18 (54.5) 10 (56.6) 28 (54.9)
Type of TB for incident cases
Smear positive pulmonary 2 (6.7) - 2 (3.9)
Smear negative pulmonary 11 (36.7) 11 (52.4) 22 (43.1)
Extra-pulmonary and/or Disseminated 17 (56.6) 10 (47.6) 27 (53.0)
Treatment outcome for TB cases
Cured or completed 22 (73.4) 18 (85.6) 40 (78.4)
Dead 6 (20.0) 1 (4.8) 7 (13.8)
Still on treatment 1 (3.3) 1 (4.8) 2 (3.9)
NA 1 (3.3) 1 (4.8) 2 (3.9)
Side effect for anti-tuberculosis
Yes 1 (3.3) - 1 (2.0)
No 29 (96.7) 21 (100) 50 (98)
IPT provided
Yes 1 (2.8) - 1 (2.0))
No 34 (98.2) 16 (100) 50 (98.0)
CPT provided
Yes 37 (94.9) 12 (100) 49 (96.1)
No 2 (5.1) - 2 (3.9)
Past History of TB
Yes 4 (9.3) 2 (25.0) 6 (11.8)
No 39 (91.7) 6 (75.0) 45 (88.2)
IPT=Isoniazid preventive therapy; CPT= Cotrimoxazole preventive therapy
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Figure 1: Time line for occurrence of tuberculosis in course of Highly Active Antiretroviral
Therapy for patients at Zewditu Memorial Hospital September 11, 2006 to October 10,
2010
5.4. Tuberculosis Incidence Density Rate (IDR)
Tuberculosis incidence rates were calculated using person-years (PY) of follow-up as a
denominator for the entire cohort and for groups classified based on socio-demographic and
clinical characteristics (Table 4). The overall tuberculosis incidence density rate (IDR) in the
cohort was 4.9 cases per 100PY [95% Confidence Interval (CI), 3.56-6.25]. Significant reduction
of IDR was observed over the four-year period. The IDR was 43.8 cases per 100PY (95%CI;
26.6-61.0) for the first year, 4.7 cases per 100PY (95%CI; 1.2-8.3) for the second year, 0.4 cases
per 100PY (95% CI; 0.4-1.2) for the third year and 0.2 cases per 100PY (95% CI; 0.16-0.5) for
the fourth year (X2 test for trend, P<0.001, Figure 2). There were no differences observed on
major factors like baseline CD4 count, IPT use or clinical stage of the disease on the proportion
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of remaining patients in the cohort from year to year. Therefore; changes in cohort composition
could not explain the observed yearly difference in the incidence density rate.
Patients with nadir CD4 cell count of less than 100 cells/ µl had TB incidence of 9.8 cases per
100PY (95% CI; 6.3-13.3) compared to 2.9 cases of TB per 100PY (95% CI; 1.6-4.10) for
patients with CD4 cell count of greater than or equal to 100 cells/ µl (P<0.001). The incidence of
TB was the highest among patients with baseline CD4 cell count <50 cells/µl (10.2/100PY, 95%
CI; 4.8-15.5). This was significantly higher when compared with the 4.1/100 PY (95% CI; 2.8-
5.4) TB incidence among patients with CD4 count >50 cells/µl (P=0.01). The TB incidence of
5.5 cases per 100PY (95% CI; 3.8-7.2) observed for patients with symptomatic clinical disease at
the start of HAART (WHO clinical stages 3 or 4] was significantly higher from the 3.4 cases per
100PY (95% CI; 1.3-5.5) incidence among WHO stage 1or 2 patients at baseline (P=0.01).
In patients who did not receive IPT, the incidence of TB was 5.3 cases per 100 PY (95% CI; 3.8-
6.8) as compared to one case of TB per 100PY (95% CI; 0.97-3.0) among those who received
IPT (P=0.02) indicating protective effect of IPT against TB. However, the incidence estimate of
TB for patients who received IPT was variable as indicated by interval estimate due to small
number of subjects in this category. No difference in the IDR was observed for socio-
demographic factors (sex, age, educational status) and for clinical characteristics like past history
of TB, baseline hemoglobin and use of cotrimoxazole preventive therapy (Table 4).
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Figure 2: The decreasing trend of incidence of tuberculosis over the course of antiretroviral
treatment
y = -13.50x + 46.05
R² = 0.682
-30
-20
-10
0
10
20
30
40
50
1 2 3 4 5TB
 Inc
ide
nce
/10
0P
Ys
Duration on HAART in years
30
Table 4: Tuberculosis incidence density rate stratified by baseline socio-demographic and
clinical characteristics of patients receiving HAART at Zewditu Memorial Hospital
September 11, 2006 to October 10, 2010
Characteristics No.of
patients
Person-years No.with TB TB IDR (95%CI) p-value a
Total patients 546 1039.35 51 4.91 (3.56-6.25)
Age (years)
15-29 106 162.49 11 6.77 (2.77-10.77)
0.37
30-44 348 692.31 35 5.05 (3.38-11.68)
> 45 92 184.55 5 2.71 (0.33-3.36
Sex
Male 225 416.86 23 5.52 (3.26-7.77) 0.55
Female 321 622.42 28 4.50 (2.83-6.16)
Occupation
Employed 189 366.63 13 3.55 (1.62-5.47) 0.18
Unemployed 245 439.86 26 5.91 (3.64-8.18)
Educational status
Illiterate 62 123.57 4 3.24 (0.06-6.42) 0.39
Literate 477 903.98 47 5.20 (3.71-6.68)
Past History of TB
Yes 94 207.41 6 2.89 (0.58-5.1) 0.33
No 445 824.14 45 5.46 (3.86-7.05)
Baseline CD4 cell
count (cells/µl)
<100 184 305.39 30 9.82 (6.31-13.34) <0.001
>100 362 733.84 21 2.86 (1.64-4.08)
Baseline CD4 cell
count (cells/µl)
<50 89 137.4 14 10.19 (4.85-15.53) 0.01
>50 457 901.9 37 4.10 (2.78-5.42)
Baseline
hemoglobin (gm/dl)
<10 48 73.1 8 10.94 (3.36-18.53) 0.11
>10 495 956.28 43 4.50 (3.15-5.84)
WHO stage
Stage 1 or 2 191 296.34 10 3.37 (1.28-5.47) 0.01
Stage 3 or 4 355 743.01 41 5.52 (3.83-7.21)
IPT
Yes 65 98.39 1 1.02 (-0.97-3.01) 0.02
No 481 940.96 50 5.31 (3.84-6.79)
CPT
Yes 511 959.67 49 5.12 (3.68-6.53) 0.76
No 35 79.69 2 2.51 -0.97-5.99)
TB, Tuberculosis ; IDR, Incidence density rate (per 100 person-years); CI, confidence interval;
IPT, Isoniazid preventive therapy; CPT, Cotrimoxazole preventive therapy, a obtained by X2 test
for the difference in TB IDR.
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5.5. Risk Factor Analysis for the Occurrence of Tuberculosis
Cox proportional hazard analyses (bivariate and multivariate regression analyses) were used to
determine risk factors for TB in patients receiving HAART. Factors found significantly
associated with the occurrence of TB in the bivariate analyses were maintained for the
multivariate analyses (Table 5). In addition, all factors with P-value of <0.3 in the bivariate
analyses were entered in to multivariate analyses. Baseline CD4 count of <100 cells/ µl [adjusted
hazard ratio; 2.8 (95%CI; 1.6-4.9, P<0.001] was a strong and independent risk factor for the
occurrence of TB during HAART. Patients with symptomatic clinical disease (WHO stage 3 or
4) at entry had twice higher risk of acquiring TB in the course of HAART compared with WHO
stage 1 or 2 patients at baseline [adjusted hazard ratio; 2.2 (95%CI;1.1-4.4, P=0.03)]. Patients
who had not received isoniazid preventive therapy were at a greater risk of developing TB during
HAART [unadjusted hazard ratio; 7.4 (95% CI; 1.02-53.57, P=0.048)] showing borderline
significance. However, the risk estimate was not more accurate as evidenced by very wide
interval estimation because only one patient developed TB from this category. In addition, the
protective effect of IPT was not significant in the multivariate analyses [adjusted hazard ratio;
4.3 (95% CI; 0.6-32.2, P=0.15). Past history of TB was not associated with risk of TB in
bivariate analysis but it was included in multivariate analysis a priori and there was a trend in
multivariate analysis towards a past history of TB having a protective effect against TB during
HAART [adjusted hazard ratio; 0.4 (95% CI; 0.2-0.9; P=0.04). Socio-demographic factors (age,
sex, educational status, occupation) and baseline hemoglobin and use of CPT were not identified
as risk factors for TB in patients receiving HAART (Table 5).
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Table 5: Cox regression analysis of predictors of tuberculosis in HIV positive cohorts
receiving HAART at Zewditu Memorial Hospital September 11, 2006 to October 10, 2010
No.with
TB
No.
with no
TB
Bivariate analysis Multivariate analysis
Variable CHR, (95%CI) P-value AHR, (95%
CI)
P-value a
Age (in years)
15-29 11 95 2.0 (0.7-5.7) 0.2 1.4 (0.4-3.7) 0.6
30-44 35 313 1.9 (0.7-4.8) 0.2 1.1 (0.2-5.3) 0.7
>45 5 87 1 1
Sex
Male 23 202 1.2 (0.7-2.1) 0.5
Female 28 293 1
Occupation
Employed 13 176 1 1
Unemployed 26 219 1.6 (0.8-3.1) 0.2 0.7 (0.3-1.3) 0.2
Educational
Status
Illiterate 4 58 0.7 (0.5-1.5) 0.4
Literate 47 430 1
Baseline
Hemoglobin
(gm/dl)
<10 8 40 2.1 (1.0-4.4) 0.06 1.8 (0.7-4.4) 0.2
>10 43 452 1 1
Baseline CD4
cell count
<100 cells/µl 30 154 3.3 (1.9-5.7) <0.001 2.8 (1.6-4.9) <0.001
>100 cells/µl 21 341 1
WHO stage
Stage 1 or 2 10 181 1 1
Stage 3 or 4 41 314 2.4 (1.2-4.8) 0.01 2.2 (1.1-4.4) 0.03
Past history of
tuberculosis
Yes 6 88 0.62 (0.26-1.46) 0.27 0.4 (0.2-0.9) 0.04
No 45 400 1 1
IPT
Yes 1 64 1 1
No 50 431 7.40 (1.02-53.57) 0.048 4.3 (0.6-32.2) 0.15
CPT
Yes 49 462 1
No 2 33 0.59 (0.14-2.42) 0.46 0.76
HR=Hazard ratio, AHR= adjusted hazard ratio; CHR=Crude hazard ratio, CI= Confidence
interval Note: All variables with a P-value of <0.3 in bivariate analyses were included in
multivariate analyses.
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The Kaplan-Meier estimates of TB-free survival proportion after initiation of HAART were
made for the overall cohort and among patients stratified by factors like baseline CD4 cell count
and WHO stage of HIV infection. The TB-free survival proportion for the entire cohort over the
four-year follow-up period was 0.88 (Figure 3).  Patients with baseline CD4 cell count of <100
cells/ µl had significantly lower probability of not developing TB than in those with >100 cells/
µl (80% versus 92%; P< 0.001 using the log rank test, figure 4). On further lowering down the
CD4 cut off point, patients with CD4 count  <50 cells/µl had significantly lower probability of
not developing TB compared to those with CD4 count of > 50 cells/µl (80% versus 88%,
P=0.03). The effect of very low CD4 count (<50 cells/µl in this case) on the probability of TB
occurrence did not show remarkable difference from CD4 count cut off value <100 cells/µl since
there were only 89 patients with CD4 count of <50 cells/µl out of which only 14 developed TB
during HAART. Likewise, patients with symptomatic clinical disease (WHO stage 3 or 4) had
slightly lower probability of not developing TB compared with those with WHO stage 1 or 2
(87% versus 88%; P=0.03) over four years. However, the gap was wide in the first three-years of
follow-up but converged as time of follow-up increased. For example, the chance for not
acquiring TB at 40 months of follow-up for WHO stage 3 or 4 patients was 87% compared with
92% TB-free survival proportion for WHO stage 1 or 2 (figure 5) indicating that WHO stage of
the disease at entry was not a strong predictor of TB occurrence for patients who stayed on
HAART for long time. The four-year TB-free survival proportion was also determined for
patients based on the use of IPT during HAART (figure 6). Patients who were not on IPT at any
time in the course of treatment had lower four-year TB-free survival proportion as compared to
those who received IPT (87% versus 97%; P=0.03).
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Figure 3: Kaplan-Meier plot of tuberculosis (TB)-free survival proportion for patients on
Highly Active Antiretroviral Therapy at Zewditu Memorial Hospital September 11, 2006 to
October 10, 2010
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Figure 4: Kaplan-Meier plot of tuberculosis (TB)-free survival proportion based on
baseline CD4 cell count (P-value from the Log rank test is given)
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Figure 5: Kaplan-Meier plot of tuberculosis (TB)-free survival proportion based on clinical
stage of the disease at entry (P-value from the log rank test given)
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Figure 6: Kaplan-Meier plot of tuberculosis (TB)-free survival proportion based on the use
of isoniazid preventive therapy (IPT)
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6. DISCUSSION
Tuberculosis and the emerging multi-drug resistant TB epidemic pose major challenges both for
the national HIV and TB control programs in resource-limited settings (32). HAART benefits the
individual patients from the occurrence of repeated opportunistic infections and reduces the
incidence of TB in treated cohorts by approximately 80% (14). However, unlike other
opportunistic infections, tuberculosis remains the most frequent infection and a leading cause of
death among patients receiving HAART particularly during the first months of treatment (33).
This study confirmed that in Ethiopia tuberculosis is still a common HIV- related complication
among patients receiving HAART with an incidence of 4.9 cases per 100PY (95% CI; 3.6-6.2).
The incidence showed a significantly decreasing trend over four-year follow-up period;
decreasing from 43.8 cases per 100 PY in the first year to 0.2 cases per 100 PY in the fourth
year. This time dependent change in TB incidence has been demonstrated in other similar long-
term follow-up studies (15, 31, 34). However, the incidence of TB in the first year of HAART in
this particular study was very high. This partly could be explained by the fact that nearly 80% of
patients in this cohort had baseline CD4 count of <200 cells/ µl indicating advanced
immunosupression, a major risk factor for TB. Among the new TB cases, 60.8% occurred in the
first three months of HAART and 53% were extra-pulmonary and/or disseminated both of which
may support Immune Reconstitution Inflammatory Syndrome (IRIS) as a factor to cause post-
HAART tuberculosis. In developing countries where HIV and TB co-infections are very
common, IRIS had been implicated for 11-47% of post-HAART tuberculosis (35). In addition,
some clinical cases might have been left undiagnosed at HAART initiation due to lack of
stringent TB screening practices or sensitivity of diagnostic techniques with persistent
immunodeficiency or both. Nevertheless, a TB incidence of 0.2 cases per 100 PY even after the
39
fourth year on HAART indicated that HIV patients on treatment still were at higher risk for
tuberculosis and occurrence of TB during HAART carried bad prognosis; mortality rate of 29.1
cases per 100PY as compared with 2.6 per 100 PY without TB (P=0.02).
Baseline CD4 cell count of <100 cells/ µl was a very strong and independent risk factor
associated with a higher risk of TB in patients receiving HAART [adjusted hazard ratio; 2.8
(95% CI; 1.6-4.9), P<0.001]. In fact, the highest TB incidence (10.2/100PY) in this cohort
analysis was observed among patients with baseline CD4 count <50 cells/µl. Lower baseline
CD4 count before initiation of HAART has consistently been indicated as an independent risk
factor for occurrence of TB during the course of HIV treatment in different settings (15, 16, 31,
34). One study in West Africa has indicated that baseline CD4 count has no any association with
the occurrence of TB during HAART (17). This was because the study had profound limitations
in design related to size of the study population, the number of TB cases, diagnostic criteria for
TB and restricted cohort composition. In multivariate analysis in our study, WHO clinical stage 3
or 4 patients carried significant risk of developing TB during follow-up compared to stage 1 or 2
patients specially in the first 2-3 years of follow-up (table 5). Unlike baseline CD4 cell count,
WHO clinical stage was not strong predictor of occurrence of TB as shown by the convergence
of survival curve after prolonged duration of HAART (Figure 5).
In general, the findings in this study indicated that more advanced pre-treatment
immunodeficiency (as indicated by very low baseline CD4 cell count and WHO clinical stage 3
or 4) retains the highest risk of TB during HAART which was consistent with results from
studies involving untreated patients (10). This may reflect the fact that the greater the degree of
40
pre-HAART immunodeficiency, the more prolonged the period of treatment required to restore
immune function. In addition, patients with advanced pre-treatment immunodeficiency are more
likely to have suboptimal immunological recovery, which has been reported both in low-and
high-income settings (26, 36-38). HIV treatment criteria in Ethiopia include only those with CD4
count of <200 cells/ µl, WHO stage 4 disease and WHO stage 3 disease with certain conditions
(27). With similar argument, treatment based on this recommendation may limit the extent to
which long-term TB-specific immune responses may be restored in many patients. This may
restrict the potential benefit of HAART for the TB control. This was evidenced in this study by
the fact that more than 80% of patients had baseline CD4 count of <200 cells/ µl and even after 4
years on HAART, the incidence of TB was still high at the level of 0.2/100PY (200/100,000).
Conflicting results have been reported for the association of past history of tuberculosis with the
subsequent occurrence of TB in patients receiving HAART. The risk of tuberculosis after
HAART was significantly higher in patients with history of TB than in those with no history of
TB in one West African study (17). This was based on 129 adults enrolled in cohort out of which
only 31 had previous history of TB and subjects were followed only for short duration. Studies
with very large sample size and longer duration of follow-up have identified that past history of
tuberculosis was not an independent risk factor for incidence of TB among patients receiving
HAART (15, 39). In fact a 5-year cohort analysis in South Africa after a median duration of
follow-up of 40 months demonstrated history of tuberculosis as protective factor for the
occurrence of TB even though there was no significant statistical association (15). Similarly, in
the bivariate analysis in this study, past history of TB was not associated with incidence of TB in
the course of HAART. However; it showed some level of protection against TB in multivariate
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analysis [adjusted hazard ratio; 0.4 (95% CI; (0.2-0.9), P=0.04). It is difficult to explain this
association as complete restoration of immunity against TB in HIV infected patients will either
not be possible or be prolonged after initial episode of TB (14, 31). It also was not possible to
identify the incident TB cases whether these were due to re-infection or reactivation of latent TB.
Nevertheless, it has been indicated that in countries with higher TB rates, most recurrences after
appropriate treatment are probably due to re-infection rather than relapse and therefore,
difference in the exposure could be mentioned as a confounding factor in this case (40).
The incidence of tuberculosis decreased from 6.7 per 100 PY for age group of 15-29 to 2.7 cases
per 100 PY for patients with age >45 years. The trend was not statistically significant in the
bivariate and multivariate Cox regression analysis indicating age was not risk factor for
occurrence of TB among patients receiving HAART in this study. Similarly, lack of association
between age and incidence of TB during antiretroviral treatment has been reported by other
studies (31, 39). On the other hand, younger age has been described as risk factor for TB during
HAART (15, 16). The later was difficult to explain as older age usually is associated with a
higher risk of tuberculosis infection and disease. However, possibility of behavioral differences
that affect exposure to HIV and subsequently to TB have been mentioned as an explanation for a
decreasing trend of TB incidence in older age (15).
Male gender has been historically linked to an increased TB incidence (41). This may be
attributable to illness behavior like symptom denial at time of presentation for ART initiation
leading to higher rates of immune reconstitution TB. Male sex has also been associated with
increased delay in diagnosis of TB (42).  Likewise, significant association of male gender with
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risk of tuberculosis among patients receiving HAART has been described in long term cohort
studies (31, 39). Another study indicated male sex to be an important risk factor for the
occurrence of TB only in the first three months of HIV treatment not then after (43) while others
have indicated that male sex is not associated with an increased risk of TB in the course of HIV
treatment (15, 16, 34). The incidence of TB among male patients on antiretroviral therapy in this
cohort study was 5.5 cases per 100 PY compared with 4.5 cases per 100 PY for females (P=0.5),
indicating absence of significant association in the difference of the incidence density rate
between sex. A sub-analysis assessing risk factors of TB in the first three months alone also
showed that male sex is not predictor of TB in patients receiving HAART.
Most cohort analyses dealing with establishment of TB incidence among HAART recipients
universally reported that most TB episodes occur in the first 3-6 months. In this study, 61% of
new TB cases were noted in the first three months after initiation of HAART and 70% occurred
in the first 6 months. The overall incidence of TB on HAART was high (4.9 cases per 100 PY).
The high TB incidence on HAART noted in this study and many others raises the issue of TB
screening in all patients at HAART initiation and provision of isoniazid preventive therapy (IPT)
to prevent incident cases (44). In Brazil and South Africa, in a much higher TB incidence setting
for example, comparing TB incidence rates between cohorts receiving no HAART, HAART only
or IPT and HAART showed that IPT can reduce the risk of TB beyond the reduction due to
HAART and called for a wider use of IPT combined with HAART (16, 45).
In this cohort analysis, the incidence of TB among patients who have not received IPT at any
time in the course of HAART was 5.3 cases per 100PY when compared with 1 case per 100 PY
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among those who received IPT in addition to HAART (p=0.02). Bivariate Cox regression
analysis showed borderline significance of the protective effect of IPT from occurrence of TB
during HAART (Table 5). In addition, the Kaplan-Meier survival analysis indicated that patients
on HAART who also received IPT, after four-years of follow-up have 10% higher TB-free
survival proportion than those who received HAART only (Figure 6). However, the protective
effect of IPT could not be established in multivariate Cox proportional hazard analysis [adjusted
hazard ratio; 0.23 (95% CI; 0.03-1.7), P=0.15]. It should be noted that only 11.9% of patients in
this cohort received IPT and analysis was made by an intention-to-treat, there by considering all
patients who began IPT equally, regardless of their completion status. Despite the presence of
enough evidence on protective effect of IPT in HIV patients, recommendation by national
guidelines, the use of IPT in this cohort was very low. Challenges to exclude subclinical TB at
baseline and the early high TB incidence during HAART demonstrated in this study and by
others could delay IPT up to few months.
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7. STRENGTHS AND LIMITATIONS OF THE STUDY
Unlike the previous cohort study done in Ethiopia (12), this study was able to describe the long-
term impact (over four years) of HAART on TB incidence and the different risk factors
associated with high TB incidence were elaborated. The analyses also allowed seeing the time-
dependent changes in incidence of TB over four years. In addition, the combined effect of IPT
and HAART on the incidence of TB was assessed in comparison with the provision of
antiretroviral treatment alone. The study has also tried to explore the treatment outcome of the
occurrence of TB among patients receiving HAART which was not possible in previous studies.
This study has some limitations. This was a retrospective cohort analysis where data were
abstracted from medical records and may suffer from missing information even though the data
abstraction process was closely monitored and extensive quality assurance measures were
employed. For example, it was not possible to compare the immune response after treatment in
both TB and non-TB cases after certain duration of HAART since CD4 cell count was not being
done regularly for most subjects. Viral load indicated by many studies as predictor of prognosis
was not included in the analysis as it was not available for almost all patients. Most patients have
CD4 cell count less than 200 cells/ µl and incidence of TB could not be seen in patients with
higher CD4 cell count, 350 cells/ µl or above for example. Almost all of the new TB cases were
presumptive cases based on sputum smear microscopy, chest X-ray or clinical diagnosis. The
absence of microbiological confirmation of TB cases which may lead in to possible under-or
over-diagnosis of TB, therefore, was another limitation. However, this is the current practice in
many sub-Saharan Africa settings. Even though the sample size was enough, the presented data
was only from one center, possibly affecting generalizability of the findings.
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8. CONCLUSION
This long-term cohort analysis with a median follow-up duration of 23 months estimated the
incidence of tuberculosis in patients receiving HAART as 4.91/100 person-years. The first 3-6
months on HAART place the patients at high risk of developing tuberculosis. The incidence of
tuberculosis in HIV patients receiving HAART showed a significant and time dependent
decreasing trend over the years. This indicates that long-term HAART confers a greater
reduction in risk of tuberculosis and as such HAART may contribute more to the TB control
program in this setting. However, the study has also shown that the incidence of TB after four
years on HAART was still higher calling for attention to other measures to effectively control
TB in HIV patients. Profound baseline immunodeficiency as shown by low CD4 count (<100
cells/µl) and WHO clinical stage 3 or 4 were independent risk factors for tuberculosis in the
course of antiretroviral treatment but none of socio-demographic factors were associated with
high risk of TB in patients on HAART. Isoniazid preventive therapy (IPT) increased the TB-free
survival proportion by 10% in patients receiving HAART after four years on HAART, though
only 11.9% of patients were given IPT in this cohort. Tuberculosis treatment outcome analysis of
incident cases has demonstrated that tuberculosis during HAART carries bad prognosis even
though death could not be attributed to TB due to lack of information on causes of death in this
study.
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9. RECOMMENDATIONS
 The incidence of TB among HIV patients on treatment was very high and requires
consistent implementation of comprehensive TB control measures including
stringent screening for TB before initiation of HAART
 HIV patients should be enrolled to treatment at higher CD4 count as
recommended in national guideline  to reduce the incidence of TB (currently one-
third of patients are enrolled in to treatment at CD4 count <100 cells/µl)
 The occurrence of one-third of TB cases with in the first month of HAART
underscores the importance of improved TB screening among HIV patients before
initiation of HAART including introduction of better diagnostic techniques
 The risk of TB remains higher even after long term treatment and this warrants
better utilization of adjunct strategies like IPT
 Prospective cohort study is recommended to demonstrate long-term restoration of
immune cell functions and to explore other strategies to reduce the TB rates
further during HAART.
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11. ANNEXES
Annex 1. Data collection tool
Incidence and risk factors of tuberculosis in patients receiving ART at Zewditu Memorial
Hospital from September 11, 2006 to October 10, 2010, data collection tool
Code No._____________
Part I: Sociodemographic characteristics
S.No Questions Categories
101 Sex Male ---------1
Female ------2
102 Age in years [enter number] ------Years (age in completed years)
103 Address Urban --------------------1
Rural ---------------------2
Not recorded------------3
104 Marital status Never married/single -----1
Married --------------------2
Separated/divorced--------3
Widowed ----- --------------4
Others (specify) ----------------
105 Religion Orthodox ------------1
Muslim ---------------2
Protestant ------------3
Catholic --------------4
Others (specify) ----------------
106 Educational status No education ----------1
Primary ----------------2
Secondary -------------3
Tertiary ----------------4
Not recorded ----------5
107 Occupation Employed-----------1
Unemployed--------2
Not recorded--------3
53
Part II: Past Tuberculosis diagnosis and treatment history
201 Does the patient have past TB treatment
history?
Yes----------------1(proceed with202)
No-----------------2 (go to question 301)
Not recorded-----3 (go to question 301)
202 Date treatment started DD/MM/YY _______________(E.C.)
203 Date treatment completed DD/MM/YY______________(E.C.)
204 Type of Tuberculosis Smear positive pulmonary ------------1
Smear negative pulmonary------------2
Extra-pulmonary ------------------------3
Other --------------------------------------4
Not recorded -----------------------------5
205 Treatment outcome Cured -------------------1
Defaulted --------------2
Treatment failure-----3
Transferred -----------4
Not recorded----------5
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Part III: HIV testing, treatment and follow-up
301 Date HIV status was known DD/MM/YY________________(E.C.)
302 Disclosure Yes--------------------1
No---------------------2
Not recorded--------3
303 If Yes, to whom? Family members-----------1
Friends ----------------------2
Relatives--------------------3
Others -----------------------4
Not recorded---------------5
304 Date ART started DD/MM/YY____________________(E.C.)
305 Regimen at the start D4T/3TC/NVP----------------1
ZDV/3TC/NVP---------------2
D4T/3TC/EFV----------------3
ZDV/3TC/EFV---------------4
Other (specify)________________
306 Substitution of Regimen Yes--------------------1
No---------------------2
307 If Yes, date substitution was made DD/MM/YY____________________(E.C.)
308 If Yes on 306, reason for substitution Toxicity/side effects--------------------1
Pregnancy/risk of pregnancy ---------2
Due to new TB---------------------------3
New drug available ---------------------4
Drug out of stock ------------------------5
Others (specify)___________________
309 Was regimen switched to 2nd line? Yes--------------------1
No---------------------2
310 If Yes, when was switching done? DD/MM/YY_____________________(E.C.)
311 CD4 count at the start of ART
__________________Cells/µl
312 Subsequent CD4 counts At 6 months ________________Cells/ µl
At 12 months _______________cells/ µl
At 18 months _______________cells/ µl
At 24 Months _______________Cells/ µl
At 30 months _______________cells/ µl
At 36 Months _______________cells/ µl
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313 WHO clinical stage at initiation of ART Stage 1 or 2---------------1
Stage 3 or 4---------------2
Not recorded------------3
314 WHO clinical stage at the last follow-up Stage 1 or 2---------------1
Stage 3 or 4---------------2
Not recorded------------3
315 Viral load at the start of ART ______________copies /ml
316 Viral load at the end of follow-up _______________copies/ml
317 Weight at the start of ART __________Kg
318 Weight at the last follow-up __________Kg
319 Total lymphocyte count at the start of
ART
_________cells/ml
320 Total lymphocyte count at end of
follow-up
________cells/ml
321 Hemoglobin at the start of ART ________mg/dl
322 Hemoglobin at the end of follow-up ________mg/dl
323 Functional status of Patient at the start
of ART
Ambulatory------------1
Working ---------------2
Bedridden-------------3
Not recorded---------4
324 Date of last follow-up DD/MM/YY__________________(E.C.)
325 Date of death for those died DD/MM/YY__________________(E.C.)
326 Date of lost to follow-up or transferred
outs
DD/MM/YY___________________(E.C.)
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Part IV: Tuberculosis screening information
401 Did Patient develop TB during follow-
up?
Yes------------1(continue with 402---)
No-------------2 (proceed to 407---)
402 When was TB diagnosis made? DD/MM/YY_____________________(E.C.)
403 Type of TB diagnosed Smear positive pulmonary TB-----------1
Smear negative pulmonary TB----------2
Extra-pulmonary TB----------------------3
Others specify ___________________
Not recorded-------------------------------4
404 Treatment outcome of Tuberculosis Cured -------------------1
Defaulted --------------2
Dead--------------------3
Treatment failure-----4
Transferred ------------5
Not recorded-----------6
405 Did patient develop side effects to TB
treatment?
Yes---------------------1
No----------------------2
406 Did patient develop side effects for
ART?
Yes --------------1
No---------------2
407 Has patient taken/is taking IPT? Yes-------------1
No--------------2
408 If Yes, Start date  for IPT DD/MM/YY____________________(E.C.)
409 If Yes on 405, End date  for IPT DD/MM/YY___________________(E.C.)
410 Has patient taken/is taking CPT Yes------------------1
No------------------2
411 If Yes, date of Start on CPT DD/MM/YY____________________(E.C.)
412 If Yes, end date for CPT DD/MM/YY_____________________(E.C.)
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Annex 2. Participant Information Sheet and Consent Form
Description of the study
Title of the study: Incidence and risk factors of tuberculosis among patients receiving HAART
in Addis Ababa, Ethiopia.
Objective of the study:  To assess the incidence and risk factors for tuberculosis in patients
receiving HAART.
Introduction
Highly active antiretroviral therapy (HAART) reduces the incidence of TB by many folds by
increasing CD4 count and through restoration of TB-specific immune system. Even though the
incidence of TB is reduced significantly during treatment, the risk remains substantially higher as
compared to HIV negative subjects. The long term effect of HAART on the incidence of TB is
affected by multiple factors such as early initiation of treatment and optimal use of ART. In
Ethiopia, patients are enrolled to treatment lately and there is little or no information on the long
term impact of HAART on TB incidence. Factors associated with higher risk of TB during
HAART are also not well characterized. Understanding the factors associated with occurrence
TB during HAART will be helpful for better management of patients and provides additional
information to formulate national TB/HIV management guidelines. Therefore; this study is
aimed at determination of the incidence and risk factors of TB among patients receiving
HAART. The proposal for the study has been approved by Institution Review Board (IRB) of
Gondar University and Addis Continental Institute of Public Health. Information which is
necessary for the study will be taken from your chart. Since the study will be conducted by
taking appropriate information from your medical chart, it will not inflict any harm on you and
the information will be taken only when you give permission, participation is totally voluntary.
You will not face any problem if you don’t allow the information to be taken from your chart and
there will also be no negative consequences on your programs. Similarly, you will not get any
incentive for agreeing to participate in the study. Your name or any other identifying information
will not be recorded on the questionnaire and all information taken from the chart will be kept
strictly confidential and in a safe place. The information retrieved will only be used for the study
purpose.
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